Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Should You Sell Your Shares of AstraZeneca Today?

Shares of pharmaceutical giant AstraZeneca  (NYSE: AZN  )  were pushed down today after the company turned down an acquisition offer from Pfizer. Pfizer had originally approached AstraZeneca with a deal valuing the company at $106 billion, but AstraZeneca turned it down. The most recently revised offer put a $120 billion price tag on AstraZeneca, but after the company turned that down as well Pfizer decided to walk away. 

So what are the near term repercussions of this lost deal? According to Motley Fool analyst Michael Finarelli, he sees the company treading water in the near term. Two of its major drugs, Nexium and Crestor, are going to be losing patent exclusivity in the next few years, which could hurt the company's bottom line considerably. That said, Mike does think that the company has some potential blockbusters in the pipeline--though it's never a good idea to blindly bet on an unproven drug.

But is that reason enough for current shareholders to abandon ship? On today's "Stock of the Day", Michael says not just yet. While today's drop isn't good news for investors, he says it shouldn't have changed a long term investor's thesis. AstraZeneca has some potential future winners in its pipeline, and investors should stay where they are for now.

How to get even more income during retirement
Social Security plays a key role in your financial security, but it's not the only way to boost your retirement income. In our brand-new free report, our retirement experts give their insight on a simple strategy to take advantage of a little-known IRS rule that can help ensure a more comfortable retirement for you and your family. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2973703, ~/Articles/ArticleHandler.aspx, 9/3/2015 3:23:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Mark Reeth

Mark Reeth is an incredibly handsome Member Liaison, and is an expert on all things Foolish. Follow him on Twitter for all of the most important Fool news.

Today's Market

updated Moments ago Sponsored by:
DOW 16,391.70 40.32 0.25%
S&P 500 1,954.29 5.43 0.28%
NASD 4,749.02 -0.96 -0.02%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 3:07 PM
AZN $32.19 Up +0.51 +1.61%
AstraZeneca plc (A… CAPS Rating: ****